Dr. Sharon Castellino is the director of the Leukemia/Lymphoma (LL) program for the Aflac Cancer and Blood Disorders Center and also serves as the co-leader of the LL biorepository and vice-chair of the Aflac Precision Medicine Program protocol. 

Dr. Castellino’s overarching research is related to outcomes and late effects in Pediatric Leukemia and Lymphoma patients and survivors, with a focus on Hodgkin Lymphoma (HL).

She is the Scientific Chair for the Hodgkin Lymphoma Program in the Children’s Oncology Group (COG). She also has leadership within the COG guidelines task force on survivorship care, with expertise in understanding hepatic late effects in childhood cancer.  As a clinical trialist she has led paradigm-changing trials for pediatric Hodgkin Lymphoma.

Her investigator-initiated research has been in retrospective data analyses of large datasets, with a focus on examining disparities in outcomes and improving outcomes for adolescents and young adults (AYA) with blood cancer.

Himalee Sabnis, MD, Assistant Professor, Pediatric Hematology/Oncology

Current Project: Late effects in pediatric patients who received tyrosine kinase inhibitors

Email: himalee.sabnis@choa.org


Tamara Miller, MD, MSCE, Assistant Professor, Pediatric Hematology/Oncology

Current Project: Current Outcomes in pediatric ALL patients

View Research Profile 


Xu Ji, PhD, Assistant Professor, Health Services Researcher

View Research Profile


Rebecca Lewis, MPH

Education: Undergraduate, University of Virginia, Charlottesville VA, Masters, Rollins School of Public Health, Emory University

Current Project: Late effects in pediatric patients who received tyrosine kinase inhibitors; validating cardiac care in childhood cancer survivors

Alexandra Cathcart, MD, Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center 

Nick DeGroote, MPH, Research epidemiologist

Holly Edington, MD, Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center

Karen Effinger, MD, MSc, Assistant Professor, Pediatrics, Emory University, Aflac Cancer and Blood Disorders Center

Tarun Jain, MD, Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center

Justine Kahn, MD, MSc, Assistant Professor, Columbia University

Lane Miller, MD, MSc, Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center 

Emily Silverman, Medical student, NYU Class of 2024

Tie X, Shin M, Pirasteh A, Ibrahim N, Huemann Z, Castellino SM, Kelly KM, Garrett J, Hu J, Cho SY, Bradshaw TJ. Personalized Impression Generation for PET Reports Using Large Language Models. J Imaging Inform Med. 2024 Apr;37(2):471-488. doi: 10.1007/s10278-024-00985-3. Epub 2024 Feb 2. PMID: 38308070; PMCID: PMC11031527.

George PE, DeGroote NP, Henderson M, Jordan K, Ziworitin-Ogola C, Castellino SM, Miller TP. Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALL. Pediatr Blood Cancer. 2024 Mar;71(3):e30825. doi: 10.1002/pbc.30825. Epub 2023 Dec 25. PMID: 38146039; PMCID: PMC10843810.

Wyatt KD, Birz S, Castellino SM, Henderson TO, Lucas JT Jr, Pei Q, Zhou Y, Volchenboum SL, Furner B, Watkins M, Kelly KM, Flerlage JE. Accelerating pediatric hodgkin lymphoma research: the hodgkin lymphoma data collaboration (NODAL). J Natl Cancer Inst. 2024 Jan 25:djae013. doi: 10.1093/jnci/djae013. Epub ahead of print. PMID: 38273668.

Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature. 2024 Jan;625(7996):778-787. doi: 10.1038/s41586-023-06903-x. Epub 2023 Dec 11. PMID: 38081297.

Lo AC, Liu A, Liu Q, Yasui Y, Castellino SM, Kelly KM, Hererra AF, Friedberg JW, Friedman DL, Schwartz CL, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine LS, Hodgson DC. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Netw Open. 2024 Jan 2;7(1):e2351062. doi: 10.1001/jamanetworkopen.2023.51062. PMID: 38241048; PMCID: PMC10799264.

Flerlage JE, Palese M, Mauz-Koerholz C, Castellino SM. Proceedings and Abstracts From the Fifth International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL) Meeting. J Pediatr Hematol Oncol. 2023 Dec 18:e1-e43. doi: 10.1097/MPH.0000000000002789. Epub ahead of print. PMID: 38113171.

Ji X, Hu X, Lipscomb J, Chow EJ, Mertens AC, Castellino SM. Utilization of cardiac tests in anthracycline-treated cancer survivors differs between young adults and children: A claims-based analysis. Cancer Med. 2023 Dec;12(24):22056-22061. doi: 10.1002/cam4.6801. Epub 2023 Dec 9. PMID: 38070180; PMCID: PMC10757126.

Parsons SK, Rodday AM, Pei Q, Keller FG, Wu Y, Henderson TO, Cella D, Kelly KM, Castellino SM. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study. J Patient Rep Outcomes. 2023 Nov 10;7(1):113. doi: 10.1186/s41687-023-00653-0. PMID: 37947987; PMCID: PMC10638179.

Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PMID: 37505794; PMCID: PMC10660893.

Ji X, Shi KS, Mertens AC, Zhao J, Yabroff KR, Castellino SM, Han X. Survival in Young Adults With Cancer Is Associated With Medicaid Expansion Through the Affordable Care Act. J Clin Oncol. 2023 Apr 1;41(10):1909-1920. doi: 10.1200/JCO.22.01742. Epub 2022 Dec 16. PMID: 36525612; PMCID: PMC10082236.

Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660. PMID: 36322844; PMCID: PMC9945772.



View More Publications

National Institutes of Health/Contracts:


Understanding the impact of the Affordable Care Act on cancer treatment and outcomes for adolescents and young adults (AYA)

Role: Co-PI

PI: Ji



Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors 

Role: Co-I

PI: Landier/Klosky



SIP 20-004. Effect of Survivorship Care Plans on Cancer Mortality

Role: Co-I

PI: Mertens/Kegler


COG-U10CA98543 - 12/1/2014-Present

AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents

Role: Study Chair

PI: Adamson

SurvivorLink - 10/1/2018-9/30/2023

Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers

Role: Advisory Board

Co-PI: Mertens/Escoffery 


COG-U10CA98543 - 6/1/2019-5/31/2023

SWOG S1826: A Phase III Randomized Study of Nivolumab or Brentuximab Vedotin plus AVD in Patients (Age >/=12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma 

Role: Pediatric Study Chair (Overall Study Chair, Alex Herrera)

PI: Adamson


K07CA211956-01A1 - 09/21/2017-08/31/2022

The goal of this project is to use electronic medical record (EMR) data to capture adverse events of therapy for pediatric cancer at two large children’s hospitals and to use EMR data to describe the incidence and risk factors of acute kidney injury in children receiving therapy to treat leukemia.

Role: Mentor Team

PI: Tamara Miller


CURE Childhood Cancer - 7/1/2017-6/30/2022 

Aflac Precision Medicine: An investigation to create a systematic institutional approach to seek novel molecular abnormalities and potential therapy targets for all high risk cancer patients from diagnosis onward

Role: Co-I; Protocol Vice-Chair

PI: Graham


Bristol-Myers Squibb - 1/2016-10/1/2019 

1LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in children and adolescents

Role: Mentor/CoPI

Hal Simon Career Development Mentor Award, Emory University School of Medicine, Department of Pediatrics, 2022

Clinical Science Research Award, Aflac Cancer and Blood Disorders Center, 2022

Honoree, Researcher Appreciation Day, Emory School of Medicine, Sept. 2020